A multicenter safety study of unlicensed investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients

S
Sherif Farag, MD

Primary Investigator

Overview

The purpose of this study is to evaluate the safety of administration of the investigational cord blood units by carefully documenting all infusion-related problems.

Description

The purpose of this study is to evaluate the safety of administration of the investigational cord blood units by carefully documenting all infusion-related problems.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Blood Transfusion
  • Age: - 100 Years
  • Gender: All

Inclusion Criteria
Patients with FDA-specified indications: Hematological malignancies, Certain lysosomal storage and peroxisomal enzyme deficiency disorders (Hurler syndrome (MPS I), Krabbe Disease (Globoid Leukodystrophy),and X-linked Adrenoleukodystrophy), Primary immunodeficiency diseases, Bone marrow failure, and Beta-thalassemia
Pediatric and adult patients of any age
Exclusion Criteria
Patients who are receiving only licensed CBUs
Cord blood transplant recipients at international transplant centers
Additional Information:
Participants will not be paid for their participation.

Updated on 09 Mar 2024. Study ID: 1207009172

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center